Despite good compliance, very low fat diet alone does not achieve recommended cholesterol goals in outpatients with coronary heart disease

European Heart Journal

Volumn 20, Issue 14, 1999, Pages 1020-1029

  Aquilani, R ^a   Tramarin, R ^a   Pedretti, R F E ^a   Bertolotti, G ^a   Sommaruga, M ^a   Mariani, P ^a   Ruffato, L ^a   Catapano, M ^b   Boschi, F ^b   Dossena, M ^b   Pastoris, O ^b  

^a Service of Psychology   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Compliance; Coronary artery disease; Hypolipidic diet; Resting energy expenditure; Secondary prevention

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; AGED; ARTICLE; CALORIC INTAKE; CALORIMETRY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; ENERGY EXPENDITURE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING CESSATION; VENOUS BLOOD;

AGED; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DIET, FAT-RESTRICTED; DIETARY FATS; ENERGY METABOLISM; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; TREATMENT FAILURE;

EID: 0033168558     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1999.1402     Document Type: Article

References (77)

1. Kannel WB, Castelli WD, Gordon T, McNamara PM. Serum cholesterol, lipoproteins and risk of coronary heart disease: The Framingham study. Ann Intern Med 1971; 74: 1-12.
2. The Lipid Research Clinics Coronary Primary Prevention Trial results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. Lipid Research Clinics Program. JAMA 1984; 251: 365-74.
3. Scandinavian Simvastatin Survival Study Group (writing committee: Pedersen TR, Kjekshus J, Berg K et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
4. Shepherd J, Cobbe SM, Ford I et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
5. Eichstädt HW, Eskötter H, Hoffmann I, Amthauer HW, Weidinger G. Improvement of myocardial perfusion by shortterm fluvastatin therapy in coronary artery disease. Am J Cardiol 1995; 76: 122A-5A.
6. Jukema JW, Bruschke AVG, van Boven AJ et al. Effect of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (Regress). Circulation 1995; 91: 2528-40.
7. Bestehorn HP, Rensing UFE, Roskamm H et al. The effect of simvastatin on progression of coronary artery disease. The Multicenter Coronary Intervention Study (CIS). Eur Heart J 1997; 18: 226-34.
8. Seiler C, Suter TM, Hess OM. Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. J Am Coll Cardiol 1995; 26: 1615-22.
9. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993; 341: 1496-500.
10. Andrews TC, Raby K, Barry J et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997; 95: 324-8.
11. Cobb MM, Teitelbamn HS, Breslow JL. Lovastatin efficacy in reducing low density lipoprotein cholesterol levels on high vs low-fat diets. JAMA 1991; 8: 997-1001.
12. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257: 3233-40.
13. Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease: A result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-98.
14. Kane JP, Malloy MJ, Ports TA, Philips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264: 3007-12.
15. Ornish D, Brown SE, Scherwitz LW et al. Can lifestyle changes reverse coronary heart disease? Lancet 1990; 336: 129-33.
16. Buchwald H, Varco RL, Matts JP et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990; 323: 946-55.
17. Bradford RH, Shear CL, Chremos AN. Expanded Clinical Evaluation of Lovastatin (Excel) study results. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991; 151: 43-9.
18. Report of National Cholesterol Education Program Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med 1988; 148: 36-69.
19. Hunninghake DB, Stein EA, Dujovne CA et al. The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med 1993; 17: 1213-9.
20. Ramsay LE, Yeo WW, Jackson PR. Dietary reduction of serum cholesterol concentration: Time to think again. Br Med J 1991; 303: 953-7.
21. Kristal AK, Bowen DJ, Curry SJ, Shattuck AL, Henry HJ. Nutrition knowledge, attitudes and perceived norms as correlated of selecting low-fat diets. Health Educ 1990; 5: 467-77.
22. Contento IR, Murphy BM. Psycho-social factors differentiating people who reported making desirable changes in their diets from those who did not. J Nutr Educ 1990; 22: 6-14.
23. Caggiula AW, Watson JE. Characteristics associated with compliance to cholesterol lowering eating patterns. Patient Educ Counsel 1992; 19: 33-41.
24. McCann B, Retzlaff BM, Dowdy A, Walden CE, Knopp RH. Promoting adherence to low-fat, low-cholesterol diets: Review and recommendations. J Am Diet Assoc 1990; 90: 1408-17.
25. Perkins KA. Weight gain following smoking cessation. J Consult Clin Psychol 1993; 61: 768-77.
26. Weir JB. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol 1949; 109: 129.
27. Harris JS, Benedict FG. A biometric study of basal metabolism in man. Washington DC: Carnegie Institute, 1919 (Carnegie Institution of Washington publication N 279).
28. Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
29. Harris WS, Held JD, Dujovne CA. The dietary RISCC rating: A novel method to assess the hyperlipidemic potential of a diet. Arteriosclerosis 1988; 8: 633a-4a.
30. Istituto Nazionale della Nutrizione. Tabelle di Composizione Degli Alimenti. Istituto Nazionale della Nutritzione, 1988.
31. Kleeinveld HA, Demaker PNM, de Haan AFJ, Stalenhouf AFH. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. Sur J Clin Invest 1993; 23: 289-95.
32. Vermaak WJH, Ubbink JB, Ungerer JPJ et al. Using changes in attributable risk to predict long-term efficacy of simvastatin treatment. Clin Chem 1992; 38: 2033-7.
33. Capurso A, Resta F, Bertolini S et al. Lipid control with low-dosage simvastatin in patients with moderate hypercholesterolemia. An Italian multicentre double-blind placebo controlled study. Eur Heart J 1992; 13: 11-16.
34. Slunga L, Johnson O, Dahlen GH. Changes in Lp (a) lipoprotein levels during the treatment of hypercholesterolemia with simvastatin. Eur J Clin Pharmacol 1992; 43: 369-73.
35. The European Study Group. Efficacy and tolerability of simvastatin and provastatin in patients with primary hypercholesterolemia (Multicountry Comparative Study). Am J Cardiol 1992; 70: 1281-6.
36. Farmer JA, Washington LC, Jones PH, Shapiro AR, Gott AM Jr, Mantell G. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. Clin Ther 1992; 14: 708-71.
37. Keech A, Collins R, Mac Mahon S et al. Three-year follow-up of the Oxford Cholesterol Study: Assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 1994; 15: 255-69.
38. Schoeller DA. How accurate is self-reported dietary energy intake? Nutr Rev 1990; 48: 373-9.
39. Sempos CT, Briefel RR, Flegal KM, Johnson CL, Murphy RS, Woteki CE. Factors involved in selecting a dietary survey methodology for national nutrition surveys. Aus J Nutr Diet 1992; 49: 96-105.
40. Briefel RR, Flegal KM, Winn DM, Loria CM, Johnson CL, Sempos CT. Assessing the nation's diet limitations of the food frequency questionnaire. J Am Diet Assoc 1993; 92: 959-62.
41. Urban N, White E, Anderson G, Curry S, Kristal A. Correlates of maintenance of a low-fat diet among women in the women's health trial. Prev Med 1992; 21: 279-91.
42. Matters RD. Fat preference and adherence to a reduced fat diet. Am J Clin Nutr 1993; 57: 378-81.
43. Perkins KA. Metabolic effects of cigarette smoking. J Appl Physiol 1992; 72: 401-9.
44. Perkins KA, Epstein LH, Morks BL, Stiller RL, Jacob RG. The effects of nicotine on energy expenditure during high physical activity. N Engl J Med 1989; 320: 898-903.
45. Perkins KA, Epstein LH, Sexton JE, Stiller RL, Jacob RG. Effects of dose, gender and level of physical activity on acute metabolic response to nicotine. Pharmacol Biochem Behav 1991; 40: 203-8.
46. Acheson KJ, Zahorrska-Markiewicz B, Pittet P, Anaatharaman K, Jequier E. Caffeine and coffee: Their influence on metabolic rate and substrate utilisation in normal weight and obese individuals. Am J Clin Nutr 1980; 33: 989-97.
47. Astrup A, Toubro S, Cannon S, Hein P, Breum L, Madsen J. Caffeine: A double-blind, placebo-controlled study of its thermogenic, metabolic and cardiovascular effects in healthy volunteers. Am J Clin Nutr 1990; 51: 759-67.
48. Duzzo AD, Jhirad R, Jenne H. Effect of caffeine on ventilatory responses to hypercapnia, hypoxia and exercise in humans. J Appl Physiol 1990; 68: 322-8.
49. Manson JE, Tosteson H, Ridker PM et al. The primary prevention of myocardial infarction. N Engl J Med 1992; 324: 1406-16.
50. Watts G, Lewis B, Brunt J et al. Effects on coronary artery disease of lipid-lowering diet plus cholesteramine, in the St Thomas' atherosclerosis regression study (STARS). Lancet 1992; 339: 563-9.
51. Gordon DJ, Probstfield JL, Garrison RJ. High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies. Circulation 1989; 79: 8-15.
52. Barter P. High-density lipoprotein and reverse cholesterol transport. Curr Opin Lipid 1993; 4: 210-7.
53. Kaufmann NA. Dietary fat and blood lipid levels: The role of monounsaturated fatty acids. Nutr Metab Cardiovasc Dis 1991; 1: 104-8.
54. Mensink RP, Katan M. Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials. Atheroscler Thromb 1992; 12: 911-9.
55. Patsch JR. Postprandial lipaemia. In: Shepherd J, ed. Lipoprotein Metabolism. Baillière's Clinical Endocrinology and Metabolism: International Practice and Research, Vol. 1. Eastbourne: WB Saunders, 1987: 551-80.
56. Gotto AM, Patsch J, Yamamoto A. Postprandial hyperlipidaemia. Am J Cardiol 1991; 68: 11A-2A.
57. Patsch J. Influence of lipolysis on chylomicron clearance and HDL cholesterol levels. Eur Heart J 1998; 19: H2-H6.
58. Schmitz G, Lackner KJ. High density lipoproteins and atherosclerosis. Curr Opin Lipid 1993; 4: 392-401.
59. Schmitz G, Williamson E. High density lipoproteins metabolism, reverse cholesterol transport of cholesterol and membrane protection. Curr Opin Lipid 1991; 2: 177-89.
60. Ehnholm CJ, Huttunen JK, Pietinen P. Effect of a diet low in saturated fatty acids on plasma lipids, lipoproteins and HDL subfractions. Atherosclerosis 1984; 4: 265-9.
61. Kay RM, Jacobs M, Katan MB, Miller NE, Lewis HB. Relationship between changes in plasma lipoprotein concentration and fecal steroid excretion in man during consumption of four experimental diets. Atherosclerosis 1985; 55: 15-23.
62. Schaefer EJ, Levy RI, Ernst ND, Van Sant FD, Brewer HB. The effects of low cholesterol, high polyunsaturated fat and low-fat diets on plasma lipids and lipoprotein cholesterol levels in normal and hypercholesterolemic subjects. Am J Clin Nutr 1981; 34: 1758-63.
63. Grundy SM. Comparison of monounsaturated fatty acids and carbohydrates for lowering plasma cholesterol. N Engl J Med 1986; 314: 745-8.
64. Mann J. Diseases of the heart and circulation: The role of dietary factors in aetiology and management. In: Garrow JS, James WPT, eds. Human Nutrition and Dietetics, Edn 9. London: Churchill Livingstone, 1993: 628.
65. Singh R, Rastogi S, Verma R, Laxmi B, Singh R, Ghosh S. Randomized controlled trial of cardioprotective diet in patients with recent myocardial infraction. Brit Med J 1992; 304: 1015-9.
66. Woollett LA, Dietschy J. Effect of long-chain fatty acids on low-density-lipoprotein cholesterol metabolism. Am J Clin Nutr 1994; 60 (Suppl): 991S-6S.
67. Anonymous NIH. Consensus development panel on triglyceride, high density lipoprotein and coronary heart disease. JAMA 1993; 269: 505-10.
68. Lamarche B, Depres JP, Pauliot MC et al. Metabolic heterogeneity associated with high plasma triglycéride or low HDL cholesterol levels in men. Arterioscler Thromb 1993; 13: 33-40.
69. Pyorala K, de Bacjer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the task force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300-31.
70. Jenkins DJA, Leeds AR, Newton C. Effect of pectin, guar gum and wheat fibre on serum cholesterol. Lancet 1975; i: 1116-7.
71. Van Horn L, Moag-Stahlberg A, Liu K. Effects on serum lipids of adding instant oats to usual American diets. Am J Public Health 1991; 81: 183-8.
72. Bartram P, Gerlach S, Scheppach W, Keller F, Kasper H. Effect of single oat bran cereal breakfast on serum cholesterol, lipoproteins and apolipoproteins in patients with hyperlipoproteinemia type II A. J Parent Ent Nutr 1992; 16: 533-7.
73. Craig WJ. Iron status of vegetarians. Am J Clin Nutr 1994; 59 (Suppl): 1233S-7S.
74. Lyritis G. Epidemiology and socio-economic cost of osteoporotic fractures in the elderly. Am J Epidemiol 1994; 139: 493-503.
75. Abelow BJ, Halford TR, Isogna KL. Cross-cultural association between dietary animal protein and hip fracture: A hypothesis. Calcif Tissue Int 1992; 50: 14-8.
76. Cumming RG, Klineberg RJ. Case-control study of risk factors for hip fractures in the elderly. Am J Epidemiol 1994; 139: 493-503.
77. Hegsted DM. Calcium and osteoporosis. J Nutr 1986; 116: 2316-9.